Lucida Medical

IW Capital has led an £8.7 million investment into Lucida Medical, a UK-based healthtech firm developing AI-powered prostate cancer diagnostics from MRI scans.

Summary of transaction details:

• Value: £8.7 million
• Sector: Healthcare & Biotech
• Advisor: Not disclosed
• Key Entities: Target – Lucida Medical; Lead Investor – IW Capital; Other investors – XTX Ventures, Macmillan Cancer Support
• Location: London, United Kingdom

Note: The funding will support expansion of Lucida’s AI diagnostic service within the NHS, aiming to improve early prostate cancer detection amid rising incidence rates.